FDA Grants ‘Breakthrough Therapy’ Status to Psychoactive Psilocybin Mushrooms, Says Startup

By Dan Nosowitz

Various parts of the cannabis plant have already received full FDA approval; a drug consisting of cannabidiol, better known as CBD, has already been approved to treat two rare forms of epilepsy. Researchers have been pushing for years for relaxed legal status to study the possible medicinal benefits of hallucinogenic drugs, and now the FDA has given psilocybin—magic mushrooms—a conditional form of research approval, according to Compass Pathways, the company granted that approval.


Allowing researchers to study the effects of otherwise banned substances is tricky; the DEA’s legal definition of schedule 1 drugs requires that they have “no accepted medical use.” That’s an immediate barrier to study, and also throws the drug into question if an “accepted medical use” is discovered. Can the drug even be a schedule 1 drug in that case? The DEA has generally refused to remove substances from the list, regardless

... read more at: https://www.ecowatch.com/fda-therapy-status-psychoactive-psilocybin-mushrooms-2617427465.html

by

Leave a Reply